These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 9724376)
1. Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Messa C; Volonté MA; Fazio F; Zito F; Carpinelli A; d'Amico A; Rizzo G; Moresco RM; Paulesu E; Franceschi M; Lucignani G Eur J Nucl Med; 1998 Sep; 25(9):1270-6. PubMed ID: 9724376 [TBL] [Abstract][Full Text] [Related]
2. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography. Im JH; Chung SJ; Kim JS; Lee MC J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371 [TBL] [Abstract][Full Text] [Related]
3. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Pirker W; Asenbaum S; Bencsits G; Prayer D; Gerschlager W; Deecke L; Brücke T Mov Disord; 2000 Nov; 15(6):1158-67. PubMed ID: 11104200 [TBL] [Abstract][Full Text] [Related]
4. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429 [TBL] [Abstract][Full Text] [Related]
5. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779 [TBL] [Abstract][Full Text] [Related]
7. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Kim YJ; Ichise M; Ballinger JR; Vines D; Erami SS; Tatschida T; Lang AE Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116 [TBL] [Abstract][Full Text] [Related]
8. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study. Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O Nucl Med Commun; 2006 Apr; 27(4):381-6. PubMed ID: 16531926 [TBL] [Abstract][Full Text] [Related]
9. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Seibyl JP; Marek KL; Quinlan D; Sheff K; Zoghbi S; Zea-Ponce Y; Baldwin RM; Fussell B; Smith EO; Charney DS; van Dyck C Ann Neurol; 1995 Oct; 38(4):589-98. PubMed ID: 7574455 [TBL] [Abstract][Full Text] [Related]
10. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807 [TBL] [Abstract][Full Text] [Related]
11. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Ahlskog JE; Uitti RJ; O'Connor MK; Maraganore DM; Matsumoto JY; Stark KF; Turk MF; Burnett OL Mov Disord; 1999 Nov; 14(6):940-6. PubMed ID: 10584667 [TBL] [Abstract][Full Text] [Related]
12. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. Ilgin N; Zubieta J; Reich SG; Dannals RF; Ravert HT; Frost JJ Neurology; 1999 Apr; 52(6):1221-6. PubMed ID: 10214747 [TBL] [Abstract][Full Text] [Related]
14. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742 [TBL] [Abstract][Full Text] [Related]
15. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745 [TBL] [Abstract][Full Text] [Related]
16. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Booij J; Tissingh G; Winogrodzka A; Boer GJ; Stoof JC; Wolters EC; van Royen EA Eur J Nucl Med; 1997 Jan; 24(1):68-71. PubMed ID: 9044880 [TBL] [Abstract][Full Text] [Related]
17. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Donnemiller E; Heilmann J; Wenning GK; Berger W; Decristoforo C; Moncayo R; Poewe W; Ransmayr G Eur J Nucl Med; 1997 Mar; 24(3):320-5. PubMed ID: 9143472 [TBL] [Abstract][Full Text] [Related]
18. A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. Goebel G; Seppi K; Donnemiller E; Warwitz B; Wenning GK; Virgolini I; Poewe W; Scherfler C Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):702-10. PubMed ID: 21174092 [TBL] [Abstract][Full Text] [Related]
19. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331 [TBL] [Abstract][Full Text] [Related]
20. Analysis of Extrastriatal Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628 [No Abstract] [Full Text] [Related] [Next] [New Search]